Regulatory approval

Published by the Health Canada.

Health Canada approved trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with BRAF V600E-mutant high-grade glioma (HGG) who have received prior radiation and/or chemotherapy.

This is written in the approval document as:

MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.

Citation

Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)